Pharmacotherapies for tuberculosis (TB) are of particular concern for their adverse effects due to the need for multiple drugs and the extensive treatment period in TB regimens. The use of multiple drugs in TB therapeutics makes it challenging to accurately attribute adverse effects with the individual drugs. This chapter covers adverse effects of mainstream anti-TB therapeutics reported during 2013 to 2014 and the content complements the earlier compilations of the Side Effects of Drugs Annual. Drugs covered under this review include rifamycins, bedaquiline, linezolid, isoniazid, ethambutol, fluoroquinolones, pyrazinamide, clofazimine, cycloserine, delamanid, dapsone, and streptomycin. While drug-specific side effects and case reports concerning rare side effects of the drugs are covered in this chapter, emerging concerns such as genetic susceptibility to specific drug-related adverse effects, mechanisms of adverse effects and drug–drug interactions are emphasized. Primary literatures including clinical studies, case reports, reviews, and meta-analyses published during 2013–2014 are covered in this review.
Weblink to abstract: http://www.sciencedirect.com/science/article/pii/S0378608015000185